Our ability to identify small RNA mutations opens a novel class of targetable biology and an opportunity for a portfolio of oligonucleotide therapeutics that target specific groups of patients https://t.co/pd7zoQCk1a
"Together, we are steadily closing the gap between RNA modality, AI, and disease biology with the shared goal of discovering and developing novel treatments in heart failure." https://t.co/pd7zoQCk1a
Over the last 3 years we’ve been characterizing small RNA mutations and developing knowledge graphs to model their role in disease. The collaboration with AstraZeneca moves us closer towards realizing our vision of bringing therapeutics from discovery... https://t.co/pd7zoQCk1a
Our ability to identify small RNA mutations opens a novel class of targetable biology and an opportunity for a portfolio of oligonucleotide therapeutics that target specific groups of patients https://t.co/pd7zoQCk1a